

Credit Suisse Ignored…


Independent AUKUS Review…


Belantamab Mafodotin Blood…

Driving Growth with Regional Investment in Transport: A £15bn Plan
Thames Water Financial Crisis: What Happens Next After KKR Deal Collapse?
Reform UK Launches Strategy to Reduce Council Spending Waste
Popular


UK Disability Benefits Reform: What It Means for You
Gibraltar Border Deal Guarantees Future Beyond Brexit

The Bee: A Platform for Bold Working-Class Writers
VE Day 80: UK Commemorates the End of WWII in Europe
Popular

Popular
Credit Suisse Ignored Bold Greensill Capital Dealings
Measured risk-taking is vital in global finance. But there is a big difference between deliberate choices and discounting reliable internal signals. Credit Suis ...



Popular

BUSINESS
Credit Suisse Ignored Bold Greensill Capital Dealings
Measured risk-taking is vital in global finance. But there is a big difference between deliberate choices and discounting reliable internal signals. Credit Suisse's participation in audacious Greensill Capital activities is a prime example of what results from institutions discounting internal caution in search of high-return prospects. Senior Credit Suisse officials started getting anonymous note ...
Belantamab Mafodotin Blood Cancer Treatment Breakthrough
For thousands of England's multiple myeloma sufferers, the recent approval of the belantamab mafodotin blood cancer medication represents a turning point. Treatment choices have been few for many people suffering from severe blood cancer, particularly if conventional treatments cease functioning. Thanks to a novel new medication, longer survival and improved outcomes are once more expected.The fir ...
Popular
Don’t Miss Out!
From the halls of Parliament to the heart of UK culture, we bring you the most important stories as they break. Stay in the know with real-time updates on politics, entertainment, sports, and more—delivered straight to your inbox.